Autologous CD34 ⁺ Cell Therapy for Refractory Angina: 2-Year Outcomes from the ACT34-CMI Study

Autologous CD34 ⁺ Cell Therapy for Refractory Angina: 2-Year Outcomes from the ACT34-CMI Study is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Autologous CD34 ⁺ Cell Therapy for Refractory Angina: 2-Year Outcomes from the ACT34-CMI Study have?

Autologous CD34 ⁺ Cell Therapy for Refractory Angina: 2-Year Outcomes from the ACT34-CMI Study has 68 citations in the OpenAlex counts ScholarIQ stores.

When was Autologous CD34 ⁺ Cell Therapy for Refractory Angina: 2-Year Outcomes from the ACT34-CMI Study published?

Autologous CD34 ⁺ Cell Therapy for Refractory Angina: 2-Year Outcomes from the ACT34-CMI Study has 2016 year in the ScholarIQ index.

What is the open-access status of Autologous CD34 ⁺ Cell Therapy for Refractory Angina: 2-Year Outcomes from the ACT34-CMI Study?

Autologous CD34 ⁺ Cell Therapy for Refractory Angina: 2-Year Outcomes from the ACT34-CMI Study has bronze oa status in the ScholarIQ index.

What is the DOI of Autologous CD34 ⁺ Cell Therapy for Refractory Angina: 2-Year Outcomes from the ACT34-CMI Study?

The DOI for Autologous CD34 ⁺ Cell Therapy for Refractory Angina: 2-Year Outcomes from the ACT34-CMI Study is on the source record.

What is the PMID of Autologous CD34 ⁺ Cell Therapy for Refractory Angina: 2-Year Outcomes from the ACT34-CMI Study?

The PMID for Autologous CD34 ⁺ Cell Therapy for Refractory Angina: 2-Year Outcomes from the ACT34-CMI Study is on the source record.

What is the OpenAlex record for Autologous CD34 ⁺ Cell Therapy for Refractory Angina: 2-Year Outcomes from the ACT34-CMI Study?

The OpenAlex for Autologous CD34 ⁺ Cell Therapy for Refractory Angina: 2-Year Outcomes from the ACT34-CMI Study is on the source record.